Ownership and insider activity for Acrivon Therapeutics, Inc. Common Stock (ACRV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool.
Price
| Price | $1.70 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-31 | Levin Michaela | A-Award | 130,000 | $272K |
| 2026-08-31 | Levin Michaela | A-Award | 30,000 | |
| 2026-08-31 | Levin Michaela | |||
| 2026-08-25 | Blume-Jensen Peter | S-Sale | 14,036 | $31K |
| 2026-08-18 | Peterson Katharine | S-Sale | 101 | $203 |
| 2026-08-18 | Miller Mary | S-Sale | 185 | $372 |
| 2026-08-18 | Gamelin Erick | S-Sale | 400 | $804 |
| 2026-08-18 | Devroe Eric | S-Sale | 604 | $1K |
| 2026-08-18 | Blume-Jensen Peter | S-Sale | 1,229 | $2K |
| 2026-08-18 | Blume-Jensen Peter | S-Sale | 484 | $973 |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $99.6M | $29.5M | $36.0M | $39.8M | $41.5M |
| Short-term Investments | 0 | 0 | $98.2M | $91.4M | $139.7M | $77.1M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.7M | $100.4M | $132.1M | $129.7M | $181.6M | $120.4M |
| Property, Plant & Equipment | $59000 | $5.8M | $6.9M | $7.9M | $8.0M | $7.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.2M | $106.6M | $181.2M | $138.3M | $196.6M | $129.7M |
| Accounts Payable | $136000 | $964000 | $904000 | $5.0M | $758000 | $2.3M |
| Short-term Debt | $58000 | 0 | 0 | 0 | $1.1M | 0 |
| Total Current Liabilities | $613000 | $2.9M | $6.5M | $13.3M | $17.2M | $15.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $10.6M | $130.4M | $10.8M | $17.1M | $19.8M | $17.2M |
| Retained Earnings | -$8.6M | -$24.9M | -$56.0M | -$116.4M | -$197.0M | -$274.9M |
| Total Equity | -$8.4M | -$23.8M | $170.5M | $121.2M | $176.8M | $112.5M |
| Total Debt | $58000 | $5.6M | $5.0M | $4.6M | $3.6M | $2.7M |
| Net Debt | -$1.5M | -$94.0M | -$122.8M | -$122.8M | -$175.8M | -$115.9M |
| Working Capital | $1.1M | $97.5M | $125.6M | $116.4M | $164.4M | $104.8M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 7.99 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -0.90 |
Profitability
| Return on Equity | -70.14% |
| Return on Invested Capital | -88.28% |
| Return on Assets | -74.91% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATYR · BMEA · CBUS · IMUX · PMVP · RLMD · RPTX
Explore sector: Healthcare · Biotechnology
More sections of ACRV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks